55 results about "Antiepileptic Agents" patented technology

The disclosure concerns a method for resistance of epilepsy by suppressing the function of alpha 1G protein of T-type calcium channels, use of suppressor of alpha 1G protein for prevention or treatment for epilepsy, knockout mice resisting epilepsy by disrupting alpha 1G subunit of T-type calcium channel, and preparation method thereof. The α1G-knockout transgenic mouse can be used for investigating the relationship between diseases particularly neuropathy or psychopathy and the function of α1G T-type calcium channel via various behavioral tests since α1G subunit is mainly expression in central nervous system (CNS) and pheripheral nervous system (PNS). Further, the α1G-knockout transgenic mouse can be used for screening antileptic agents.

Medical electrical lead systems and related methods are described. The lead systems may be configured to be at least partially implanted in neural tissue of a subject, such as a brain of a subject. Some variations of the lead systems may comprise a lead body, an electrode connected to the lead body, and a bioactive agent. The electrode and / or lead body may comprise a substrate, and the bioactive agent may be supported by the substrate (e.g., by a substantial portion of the area of the substrate). Examples of bioactive agents that may be used in the lead system include antiproliferative agents, bactericidal agents, bacteriostatic agents, antiepileptic agents, and / or antifungal agents. Methods described herein may comprise coating a lead body and / or an electrode of a medical electrical lead system with at least one bioactive agent, where the lead body and the electrode are connected to each other.

The present invention is directed to novel sulfamide derivatives, pharmaceutical compositions comprising said compounds and methods for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, said compounds, either alone or as co-therapy with one or more anticonvulsant and / or anti-epileptic agents.

The invention provides a bi-path detecting card capable of simultaneously detecting carbamazepine and sodium valproate and a detecting method of the same, and belongs to the technical field of the monitoring on the blood concentration of antiepileptic drug. In the invention, a detecting window and a sample adding hole are arranged on the surface of a shell of the detecting card; a testing bar is arranged in the shell; a nitrocellulose film is adhered to the middle part of a backing board of the testing bar; a water absorbent film is adhered to one end of the backing board; a sample pad is adhered to the other end of the backing board; two segments of colloidal gold films are arranged between the water absorbent film and the sample pad in an adhesive manner; the colloidal gold films are respectively glass fiber films containing colloidal gold markers of monoclonal antibodies resistant to the carbamazepine and the sodium valproate; three separated imprint display strips are transversely arranged on the nitrocellulose film, and include a detecting strip containing carbamazepine protein conjugate, an another detecting strip containing sodium valproate protein conjugate and a quality control strip containing antibodies resistant to a rabbit or a rat; the sample pad is just opposite to the sample adding hole; and the nitrocellulose film is just opposite to the detecting window. The detecting card can be used for simultaneously detecting components of two anticonvulsants in a serum sample, and has the advantages of saved cost for detection, convenience for use, quickness in detection, high sensitivity and accuracy in result.

The present invention is directed to the combined use of BACE1 inhibitor of Formula Iand a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive Aβ peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.

The invention belongs to the field of gene detection, and in particular relates to a gene detection kit for individualized antiepileptic drug administration and its application. The kit provided by the present invention mainly includes library primer mixture, multiplex PCR library amplification buffer, digestion buffer, ligation buffer, ligase, specific linker, HiFi library amplification buffer, positive / negative quality control, Reporting system, instructions. The kit provided by the invention can be used to detect 10 commonly used anti-epileptic clinical drugs, with a total of 44 genes and 103 detection sites; it realizes the related gene detection and report analysis for the prediction of the curative effect and adverse reactions of anti-epileptic drugs. medication assistance.

The present invention refers to a pharmaceutical composition comprising racetam and carnitine. Said pharmaceutical composition may further comprise coenzyme QlO and / or agent associated with mitochondrial and / or metabolic disturbance,such as hypocholesterolemic agent of the statins group, a hypoglycemic agent, or an antiepileptic agent. The invention also includes a method of treatment for mitochondrial disturbances comprising administration of the pharmaceutical composition of the invention.

The invention discloses a fluorescence detection method for antiepileptic drug tiagabine hydrochloride (TGB). Through the study of the interaction of dye perylene diimide derivatives (PDI), human serum albumin (HSA) and tiagabine hydrochloride (TGB), we found that the fluorescence of PDI can be quenched by HSA, and our research It shows that PDI binds at site II of HSA, and TGB can compete for binding at site II of HSA, so that PDI is competed from site II of HSA, thereby realizing fluorescence recovery. Based on this, the present invention proposes a fluorescence detection method for TGB, which uses PDI‑HSA as a probe to realize fluorescence recovery under the action of TGB, so as to detect TGB. The method of the invention has the advantages of original innovation, simple detection process, mild experimental conditions, high sensitivity, good selectivity, fast detection time, low detection limit, etc., and has good social value and application prospect.